RESEARKA

Several unresolved questions complicate any synthesis of metformin effects across the aging-relevant evidence base. Mechanistic translation from cell and animal models to human aging biology remains incomplete, as AMPK activation, mTOR inhibition, and mitochondrial effects demonstrated in preclinical systems may not scale proportionally or may produce context-dependent trade-offs in human tissues. Metformin effects on insulin sensitivity appear to differ between rest and exercise conditions, with evidence suggesting that the drug may attenuate exercise-induced metabolic adaptations in adults at risk for metabolic syndrome (Malin 2026), raising the possibility that co-prescription with lifestyle interventions could yield paradoxical outcomes. Population specificity is another critical gap: most trial data derive from type 2 diabetes cohorts, yet repurposing for aging would target broader, often non-diabetic populations, and pregnancy, pediatric, and very elderly contexts introduce distinct risk-benefit calculations (Brinkmann 2025; Newman 2026; Schoenaker 2026). Dose-response relationships for non-glycemic endpoints remain poorly characterized, and the question of whether metformin effects require chronic exposure or can be detected with shorter treatment durations has not been systematically addressed. The translation question is critical: whether these diabetic-population benefits extend to normoglycemic older adults is being addressed by trials such as MET-PREVENT, which targets sarcopenia and physical prefrailty (Rennie 2022). Metabolic syndrome risk modification has been explored in exercise-training paradigms, though metformin attenuated some insulin-sensitivity adaptations in at-risk adults (Malin 2026), illustrating that Metformin Effects may operate differently depending on metabolic context.

Citation Support

• source_1 Zaveri 2026
• source_2 Wu 2026
• source_3 Hong 2026
• source_4 Lee 2026
• source_5 Seo 2026